Modulim is a pioneer in optical imaging solutions powered by spatial frequency domain imaging (SFDI) for noninvasive tissue and vascular assessment. Powered by SFDI, our Clarifi® Imaging System helps clinicians identify patients at-risk of complications due to microvascular dysfunction. The #ClarifiImagingSystem quantifies and maps five biomarkers of microvascular tissue oxygenation and perfusion. As a result, clinicians can quickly identify at-risk patients for earlier and more timely intervention so they may prevent complications such as diabetic foot ulcers and amputations. With its widespread adoption, our technology solutions have the potential to save limbs and lives, improve outcomes and reduce costs across the continuum of care by enabling early detection and intervention. Clarifi is affordable and easily integrated into a clinician’s practice. Clarifi imaging is supported by reimbursement (Current Procedural Terminology (CPT®) Proprietary Laboratory Analyses (PLA) code (0061U). Our proprietary technology - SFDI - was invented by Modulim's founder and CTO David Cuccia, Ph.D., and his colleagues at UC Irvine’s Beckman Laser Institute. SFDI is a noninvasive tissue oxygen saturation technology that combines structured illumination with multiple wavelengths of light (visible and near-infrared) to allow for deeper and layer-specific assessment of tissue oxygenation and hemoglobin. This unique technology deciphers the reflection, absorbance, and scattering of light in tissue. Both David and Amaan Mazhar, Ph.D., Modulim’s VP of Research & Development, are both internationally-recognized experts in the field of medical photonics. #seebeyond